Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VD's Model Portfolio & Discussion Thread -- Ignore unavailable to you. Want to Upgrade?

To: Vector1 who wrote (5145)	6/18/1998 8:00:00 PM
From: scaram(o)uche	Respond to of 9719

V1: Well, then you missed my antagonism on the thread. I do not believe that the company (LGND) has been shareholder friendly. However, I appreciate and share most of your logic. As it cratered and as rumors swirled regarding the agonist/Science manuscript, I opted for November 12 1/2s. Given a research premium of 500 million and almost no cushion, any negative data from a phase II will kick the shares, and I thought that I could buy, for the same risk, about 2X the share leverage with calls. That is, I believe that negative data from either the prostate or breast trials will hand you shares at about $8, and the calls were 2 1/4. Of course, if we trade under $13-14 until October and under $15 through November, I kiss 100% goodbye. I plan to provide a little protection on any rally, and the damn SRGN news was not what I needed. Note, however, that the share price didn't decline too much this morning on news from FDA, but then got hit harder when it was clearer that the product was not in serious trouble. :-) It is only coincidence that we have discussed AGPH and LGND today and that I have an options strategy for both. I don't usually do this. Rick